Tumor Targeting and Penetration Technology Platform – Lisata Therapeutics | GCFF

Published on: Jun 15, 2023
Author: Editor

LisataTherapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively.

Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The company projects the announcement of many clinical study and business milestones over the next 2 years, having indicated that its current business and development plan is funded with available capital through these milestones and into early 2026.

For more information, please visit their website.

Download the PPT here.

Corporate Speaker:

David J. Mazzo, PhD,
President & CEO

David J. Mazzo, Ph.D., is the Chief Executive Officer of Lisata Therapeutics, Inc., having joined the Company in January 2015. He is a pharmaceutical executive and strategic leader with broad experience in both large and small companies gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia. He has held executive positions in R&D at large multinational companies such as Hoechst Marion Roussel and Schering-Plough as well as CEO positions in emerging pharmaceutical companies such as Chugai USA, Aeterna Zentaris and Regado Biosciences. He is recognized for his exceptional strategic, scientific and regulatory expertise, upon which he has amassed a track record of more than 35 years of successful global product development, registration and launch.

Dr. Mazzo is also a seasoned public and private company director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals (where he was Chairman of the Board) and Seneca Biopharma. He currently is the Chairman of the Board of Visioneering Technologies, Inc. (ASX:VTI), a developer and marketer of therapeutic contact lenses for pediatric myopia and presbyopia, and a Director of Feldan Therapeutics, a private company developing novel technology for the intracellular delivery of therapeutics.

Dr. Mazzo earned his Ph.D. in Analytical Chemistry as well as an M.S. in Chemistry at the University of Massachusetts (Amherst). He also holds dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.

Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.

GCFF Life Science Pharmaceutical